Citius Oncology, Inc. (CTOR)

Citius Oncology Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Cash & Equivalents	0	0	-	-
Cash & Short-Term Investments	0	0	-	-
Inventory	15.34	8.27	-	-
Prepaid Expenses	2.7	2.7	7.73	2.69
Total Current Assets	18.04	10.97	7.73	2.69
Long-Term Deferred Charges	73.4	73.4	40	40
Total Assets	91.44	84.37	47.73	42.69
Accounts Payable	7.68	3.71	1.29	0.09
Accrued Expenses	13.66	0.59	19.76	5.75
Other Current Liabilities	28.4	28.4	-	-
Total Current Liabilities	49.74	32.7	21.05	5.85
Long-Term Debt	3.8	3.8	-	-
Long-Term Deferred Tax Liabilities	2.26	1.73	1.15	0.58
Other Long-Term Liabilities	-	-0	-	-
Total Liabilities	55.8	38.23	22.2	6.42
Common Stock	0.01	0.01	0.01	0.01
Additional Paid-In Capital	89.31	85.41	43.66	41.69
Retained Earnings	-53.67	-39.28	-18.13	-5.43
Shareholders' Equity	35.64	46.14	25.54	36.27
Total Liabilities & Equity	91.44	84.37	47.73	42.69
Total Debt	3.8	3.8	-	-
Net Cash (Debt)	-3.8	-3.8	-	-
Net Cash Per Share	-0.05	-0.06	-	-
Filing Date Shares Outstanding	71.55	71.55	67.5	67.5
Total Common Shares Outstanding	71.55	71.55	67.5	67.5
Working Capital	-31.7	-21.73	-13.31	-3.16
Book Value Per Share	0.50	0.64	0.38	0.54
Tangible Book Value	35.64	46.14	25.54	36.27
Tangible Book Value Per Share	0.50	0.64	0.38	0.54

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q